ARID1A	AT-rich Interaction Domain 1A
ASPEN	A Study of Pharmacodynamics and Efficacy in Non-Hodgkin Lymphoma
BAD	Bcl-2-Associated Death promoter
BAX	Bcl-2-Associated X protein
BTK	Bruton’s Tyrosine Kinase
CBA	Chromosome Banding Analysis
CD19	Cluster of Differentiation 19
CD79A	Cluster of Differentiation 79A
CD79B	Cluster of Differentiation 79B
CHIP	Clonal Hematopoiesis of Indeterminate Potential
CXCR4	C-X-C Motif Chemokine Receptor 4
DLBCL	Diffuse Large B-Cell Lymphoma
DNA	Deoxyribonucleic Acid
FISH	Fluorescence In Situ Hybridization
GPER1	G-Protein-Coupled Estrogen Receptor 1
IGHV	Immunoglobulin Heavy Chain Variable
IgM	Immunoglobulin M
LPL	Lymphoplasmacytic Lymphoma
MDM2	Mouse Double Minute 2
MGUS	Monoclonal Gammopathy of Undetermined Significance
MWCL-1	Mantle-Cell Lymphoma Cell Line 1
MYD88	Myeloid Differentiation Primary Response 88
NF-κB	Nuclear Factor kappa-light-chain-enhancer of activated B cells
OS	Overall Survival
P21	Cell Circle Inhibitor P21
PFS	Progression-Free Survival
PUMA	p53 Upregulated Modulator of Apoptosis
TMNs	Therapy-related Myeloid Neoplasms
TP53	Tumor Protein 53
TTP	Time To Progression
TTT	Time To Treatment
WHIM	Warts, Hypogammaglobulinemia, Infections, and Myelokathexis
WM	Waldenström Macroglobulinemia